PLCG2 was strongly associated with the development of leukemia, and its activity was a potential biomarker of response in CLL and diffuse large B-cell lymphoma (DLBCL) treatment. This evidence concerns the gene PLCG2 and B-cell chronic lymphocytic leukemia.